Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomethorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 8/20 | 0.98 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.98 |
| ▸ | GRIN2D | O15399 | 7/20 | 0.98 |
| ▸ | GRIN3B | O60391 | 7/20 | 0.98 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.98 |
| ▸ | GRIN2C | Q14957 | 7/20 | 0.98 |
| ▸ | GRIN3A | Q8TCU5 | 7/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.98 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemethorphan SCHEMBL15349020 | 1.00 | CYP3A4 (1.00) | CYP3A4GRIN1GRIN2AGRIN2DGRIN3B | |
| Racemethorphan SCHEMBL6855351 | 1.00 | CYP3A4 (1.00) | CYP3A4GRIN1GRIN2AGRIN2DGRIN3B | |
| Dextromethorphan SCHEMBL29354383 | 1.00 | CYP3A4 (1.00) | CYP3A4GRIN1GRIN2AGRIN2DGRIN3B | |
| Dextromethorphan SCHEMBL121924 | 1.00 | CYP3A4 (1.00) | CYP3A4GRIN1GRIN2AGRIN2DGRIN3B | |
| Dextromethorphan SCHEMBL1321395 | 0.99 | CYP2D6 (1.00) | CYP3A4GRIN1GRIN2AGRIN2DGRIN3B | |
| Levomethorphan SCHEMBL4910539 | 0.99 | CYP2D6 (1.00) | CYP3A4GRIN1GRIN2AGRIN2DGRIN3B | |
| Racemethorphan SCHEMBL4894005 | 0.99 | CYP2D6 (1.00) | CYP3A4GRIN1GRIN2AGRIN2DGRIN3B | |
| Dextromethorphan SCHEMBL121923 | 0.99 | CYP2D6 (1.00) | CYP3A4GRIN1GRIN2AGRIN2DGRIN3B | |
| Dextromethorphan SCHEMBL4882308 | 0.99 | CYP3A4 (0.98) | CYP3A4GRIN1GRIN2AGRIN2DGRIN3B | |
| Dextromethorphan SCHEMBL4532860 | 0.99 | CYP2D6 (1.00) | CYP3A4GRIN1GRIN2AGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-30 | — | — | US | claimed |
| EP-2841067-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | The Regents of The University of California (US) | 2015-03-04 | — | — | EP | claimed |
| WO-2013163455-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-31 | — | — | WO | claimed |
| US-20080146805-A1 | dissolving the morphinan in the biphasic mixture, extracting the organic layer including the morphinan with a water soluble amine base, isolating the morphinan, forming a salt of the morphinan, crystallizing | MALLINCKRODT INC. (US) | 2008-06-19 | — | — | US | claimed |
| EP-1781616-A2 | PROCESS FOR THE PRODUCTION OF LEVORPHANOL AND RELATED COMPOUNDS | MALLINCKRODT, INC. (US) | 2007-05-09 | — | — | EP | claimed |
| WO-2006023669-A2 | PROCESS FOR THE PRODUCTION OF LEVORPHANOL AND RELATED COMPOUNDS | MALLINCKRODT INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200390780-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2020-12-17 | — | — | US | disclosed |
| US-10851063-B2 | Methods for preparing levorphanol and related compounds, and compositions thereof | AMPAC FINE CHEMICALS LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-10660899-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200109119-A1 | METHODS FOR PREPARING LEVORPHANOL AND RELATED COMPOUNDS, AND COMPOSITIONS THEREOF | AMPAC FINE CHEMICALS LLC | 2020-04-09 | — | — | US | disclosed |
| US-20170136029-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | IRM LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-9592288-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-14 | — | — | US | disclosed |
| US-20080146805-A1 | dissolving the morphinan in the biphasic mixture, extracting the organic layer including the morphinan with a water soluble amine base, isolating the morphinan, forming a salt of the morphinan, crystallizing | MALLINCKRODT INC. (US) | 2008-06-19 | — | — | US | disclosed |
| EP-1781616-A2 | PROCESS FOR THE PRODUCTION OF LEVORPHANOL AND RELATED COMPOUNDS | MALLINCKRODT, INC. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006023669-A2 | PROCESS FOR THE PRODUCTION OF LEVORPHANOL AND RELATED COMPOUNDS | MALLINCKRODT INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-0701434-B1 | PREPARATIONS CONTAINING SILICON DIOXIDE TO IMPROVE THE TASTE THEREOF | WARNER LAMBERT CO (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1166801-A1 | Preparations containing silicon dioxide to improve the taste thereof | WARNER-LAMBERT COMPANY (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-0701434-A1 | PREPARATIONS CONTAINING SILICON DIOXIDE TO IMPROVE THE TASTE THEREOF | WARNER-LAMBERT COMPANY (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994028870-A1 | PREPARATIONS CONTAINING SILICON DIOXIDE TO IMPROVE THE TASTE THEREOF | WARNER-LAMBERT COMPANY (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146805-A1 | dissolving the morphinan in the biphasic mixture, extracting the organic layer including the morphinan with a water soluble amine base, isolating the morphinan, forming a salt of the morphinan, crystallizing | OPRM1, OPRD1, MB | GRIN2A 583/4885SIGMAR1 7/4885CYP3A4 356/4885 |
| US-10851063-B2 | Methods for preparing levorphanol and related compounds, and compositions thereof | OPRM1, OPRK1, OPRD1 | GRIN2A 1011/4885SIGMAR1 16/4885CYP3A4 15/4885 |
| US-20200109119-A1 | METHODS FOR PREPARING LEVORPHANOL AND RELATED COMPOUNDS, AND COMPOSITIONS THEREOF | OPRM1, OPRK1, OPRD1 | GRIN2A 1011/4885SIGMAR1 16/4885CYP3A4 15/4885 |
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | GRIN2A, GRIN1, GRIN2B | GRIN2A 1/4885SIGMAR1 2078/4885CYP3A4 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.